Matching articles for "darolutamide"
Issue 1679 · June 19, 2023 Free
In Brief: A New Prostate Cancer Indication for Darolutamide (Nubeqa) (online only)

The androgen receptor inhibitor darolutamide ( Nubeqa – Bayer) has been approved by the FDA for use in combination with docetaxel for treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The…

Med Lett Drugs Ther. 2023 Jun 19; 65(1679):e108 doi:10.58347/tml.2023.1679h
The androgen receptor inhibitor darolutamide ( Nubeqa – Bayer) has been approved by the FDA for use in combination with docetaxel for treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The drug was previously approved for treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC).
Issue 1587 · December 16, 2019
Darolutamide (Nubeqa) for Prostate Cancer

The FDA has approved darolutamide ( Nubeqa – Bayer), an androgen receptor inhibitor, for oral treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Darolutamide is the third androgen…

Med Lett Drugs Ther. 2019 Dec 16; 61(1587):201-2
The FDA has approved darolutamide ( Nubeqa – Bayer), an androgen receptor inhibitor, for oral treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Darolutamide is the third androgen receptor inhibitor to be approved for this indication; apalutamide (Erleada) and enzalutamide (Xtandi) , which are also approved for use in patients with metastatic castration-resistant prostate cancer (mCRPC), were approved earlier.